An hour before the market closed on Thursday, as news reports of Trump’s choice began trickling out, Covid-19 vaccine maker Moderna dipped as much as 6 per cent, and Pfizer fell almost 2 per cent.
Novavax, which created a protein-based Covid-19 vaccine, fell almost 6 per cent.
Kennedy has been one of the country’s most prominent anti-vaccine conspiracy theorists for years and has frequently spread falsehoods about the safety and efficacy of vaccines.
Last week, Kennedy said he would “immediately” begin studying vaccine safety and efficacy but promised to not “take vaccines away from anybody.”
Trump chooses anti-vaccine activist Robert F. Kennedy Jr. as health secretary
Other vaccine-related companies also felt the fallout. German company BioNTech closed 7 per cent lower, and British GSK fell 2 per cent.
US vaccine companies have already been struggling, thanks to lessened demand since the peak of the pandemic.
Over the past year, Pfizer stock has dipped 11 per cent, and Moderna stock has plunged 46 per cent.
While Pfizer revenue and profits soared during the peak of the pandemic – generating nearly $US57 billion ($AUD88.18 Billion) in combined sales in 2022, thanks largely to its Comirnaty Covid-19 vaccine and Paxlovid antiviral pill – the boom subsided by early 2023, and the company slashed its expectations for Covid-related sales.
By then, public health agencies already had an effective stockpile of vaccines to treat patients.
After Trump made the announcement official, the stocks fell further.